Radioimmunoassay Market Expected to Expand at a Steady Cagr Through 2026

Quantification of a specific protein in a complex sample is a valuable contribution in the field of medical science. Immunoassays use the highly specific antibodies to target specific molecule of interest and analyze its concentration in a sample. Thus, immunoassay can be defined as a biochemical procedure which is used to measure the concentration of specific antigen with a specific antibody. The first immunoassay was developed in 1959 wherein radiolabeled insulin was used to determine the concentration of insulin in human plasma. Radioimmunoassay (RIA) is a medical diagnostic procedure used to measure the concentration of specific antigens by using specific antibodies. RIA is a highly sensitive technique using which any biological substance for which a specific antibody exists can be quantified, in a very minute concentrations. Radioimmunoassay is the first immunoassay technique using which Nano molar and Pico molar concentrations of hormones in biological fluids can be determined. RIA technique relies on a very basic principle of competitive binding where a radioactive antigen competes with non-radioactive antigen for a specific antibody. RIA technique finds application in various areas of disease diagnosis such as it is used in early detection and diagnosis of cancer, it is also used in diagnosis of various other infectious diseases including neurodegenerative disorders. RIA is considered as one of the most pivotal and traditional method used for endocrine disorders diagnosis. In pharmaceutical industry RIA is used for drug testing. The market for RIA is expected to witness a significant growth rate over the forecast period owing to rising use of radioimmunoassay techniques in cancer diagnosis and advancements in medical research.

The global radioimmunoassay market is expected to exhibit a single digit CAGR over the forecast period (2016-2026).

Radioimmunoassay Market: Drivers and Restraints

The global radioimmunoassay market is expected to experience...